Table 5 Differences between surviving and non-surviving patients

Type of infection

 Mold infection

17 (77.3%)

6 (100%)

 Yeast infection

5 (22.7%)

0 (0%)

Site of disease

 Bronchopulmonary disease

17 (77.3%)

6 (100%)

 Bloodstream disease

5 (22.7%)

0 (0%)

Epidemiological data

 Age (years)

10.1 (6.3-14.9)

6.9 (2.2-16)

 Sex: male

10 (45.5%)

4 (66.7%)

Number of host factors

2 (1-3.3)

3 (2.5-4)

Host factors

 Prolonged neutropenia

7 (38.9%)

2 (40%)

 Hematologic malignancy

9 (40.9%)

5 (83.3%)

 Allogeneic HSCT

8 (36.4%)

3 (50%)

 Prolonged use of corticosteroids

7 (43.8%)

4 (66.7%)

 Acute GVHD

3 (13.6%)

2 (33.3%)

 Chronic GVHD

2 (9.1%)

2 (33.3%)

Risk stratification

 High-risk

15 (68.2%)

5 (83.3%)

 Low-risk

2 (9.1%)

1 (16.7%)

 Sporadic

5 (27.7%)

0 (0%)

Antifungal prophylaxis

15 (68.2%)

5 (83.3%)

Laboratory parameters

 Haemoglobin (g/dl)

8.9 (8.2-11.2)

8.2 (7.5-10.5)

 Platelets x10³/µL

51 (27.5-114)

40.5 (10.3-66.5)

 Leukocytes/µL

1200 (250-1200)

1350 (175-5000)

 Neutrophils/µL; median (IQR)

200 (7-3975)

100 (0-4250)

 Lymphocytes/µL; median (IQR)

500 (200-1320)

450 (100-950)

 CRP (mg/dl) at diagnosis

3.9 (0.7-8.6)

10.1 (4.8-33.3)

 Maximum CRP (mg/dl)

11.5 (2.2-20.1)

13.5 (10.1-34.7)

 Procalcitonine (ng/ml) at diagnosis

0.1 (0.07-0.7)

0.2 (0.09-4.2)

 Maximum procalcitonine (ng/ml)

0.7 (0.3-1.8)

0.6 (0.3-4.2)

 GM in serum (mold infections)

0.25 (0.13-0.6)

0.6 (0.34-4.7)

 GM in BAL (mold infections)

0.19 (0.13-1.84)

0.2 (0.19-0.2)

IFD diagnosis

 Proven IFD

5 (22.7%)

1 (16.7%)

 Probable IFD

6 (27.3%)

2 (33.3%)

 Possible IFD

11 (50%)

3 (50%)

Treatment duration (days)

51 (37-72)

11 (6-32)

Outcome

 PICU admission

4 (18.2%)

4 (66.7%)

 Mechanical ventilation

0 (0%)

3 (50%)

 Inotropic support

1 (4.5%)

3 (50%)